Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 1, 2011, Pages 1-8

  Connick, Elizabeth ^a   Bosch, Ronald J ^b   Aga, Evgenia ^b   Schlichtemeier, Rick ^a   Demeter, Lisa M ^c   Volberding, Paul ^d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD4 positive T lymphocytes; CD8 positive T lymphocytes; Cytotoxic T lymphocytes; Highly active antiretroviral therapy; HIV infections; Treatment interruption

Indexed keywords

ALLOANTIGEN; ANTIRETROVIRUS AGENT; GAMMA INTERFERON; BACTERIAL ANTIGEN; FUNGUS ANTIGEN; VIRUS ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MALE; PRIMARY INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT WITHDRAWAL; VIRUS LOAD; BLOOD; CELL PROLIFERATION; DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; METABOLISM; VIRUS REPLICATION;

ADULT; ANTIGENS, BACTERIAL; ANTIGENS, FUNGAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MALE; RNA, VIRAL; VIRUS REPLICATION;

EID: 80155192413     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318224d0c7     Document Type: Article

References (36)

1. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-579.
2. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. 1989;299:154-157. (Pubitemid 19186660)
3. Schacker TW, Hughes JP, Shea T, et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med. 1998;128:613-620. (Pubitemid 28169637)
4. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
5. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med. 2001;193:169-180. (Pubitemid 32524449)
6. + T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056-8063. (Pubitemid 24362694)
7. Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009;23:1987-1995.
8. Betensky RA, Connick E, Devers J, et al. Shipment impairs lymphocyte proliferative responses to microbial antigens. Clin Diagn Lab Immunol. 2000;7:759-763.
9. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998;178:70-79. (Pubitemid 28328078)
10. Weinberg A, Spritzler J, Nokta M, et al. In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits. Clin Vaccine Immunol. 2008;15:1398-1409.
11. Palmer BE, Boritz E, Blyveis N, et al. Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4 (+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J Virol. 2002;76:5925-5936. (Pubitemid 34556287)
12. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-1450. (Pubitemid 27509814)
13. Bull M, Lee D, Stucky J, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods. 2007;322:57-69. (Pubitemid 46560582)
14. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1:e36.
15. Goujard C, Marcellin F, Hendel-Chavez H, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses. 2007;23:1105-1113. (Pubitemid 47571934)
16. Rizzardi GP, Lazzarin A, Pantaleo G. Potential role of immune modulation in the effective long-term control of HIV-1 infection. J Biol Regul Homeost Agents. 2002;16:83-90. (Pubitemid 34495596)
17. Jacobson JM, Pat Bucy R, Spritzler J, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis. 2006;194:623-632. (Pubitemid 44297848)
18. Plana M, Garcia F, Oxenius A, et al. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr. 2004;36:791-799. (Pubitemid 38859344)
19. + T cells. Nature. 2002;417:95-98. (Pubitemid 34498823)
20. Seth N, Kaufmann D, Lahey T, et al. Expansion and contraction of HIV-specific CD4 T cells with short bursts of viremia, but physical loss of the majority of these cells with sustained viral replication. J Immunol. 2005;175:6948-6958. (Pubitemid 41598941)
21. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis. 2005;192:607-617. (Pubitemid 41099309)
22. Chen H, Piechocka-Trocha A, Miura T, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009;83:3138-3149.
23. Pereyra F, Jia X, McLaren PJ, et al, for the International HIV Controllers Study. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science. 2010;330:1551-1557.
24. Ellefsen K, Harari A, Champagne P, et al. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. Eur J Immunol. 2002;32:3756-3764. (Pubitemid 36024411)
25. Hess C, Altfeld M, Thomas SY, et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet. 2004;363:863-866. (Pubitemid 38368837)
26. Daucher M, Price DA, Brenchley JM, et al. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virusspecific CD8+ T cells. J Virol. 2008;82:4102-4114. (Pubitemid 351521245)
27. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med. 2007;204:2473-2485. (Pubitemid 47529331)
28. Barker E, Mackewicz CE, Reyes-Teran G, et al. Virological and immunological features of long-term human immunodeficiency virusinfected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood. 1998;92:3105-3114. (Pubitemid 28492316)
29. Connick E. Immune reconstitution in HIV-1-infected individuals treated with potent antiretroviral therapy. J Investig Dermatol Symp Proc. 2001;6:212-218. (Pubitemid 33758577)
30. + T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116. (Pubitemid 27450659)
31. + cell numbers and clinical staging. J Clin Invest. 1989;84:1892-1899. (Pubitemid 20016195)
32. + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis. 1995;172:79-87.
33. + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. (Pubitemid 44837777)
34. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826.
35. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301:2380-2382.
36. Hogan C, De Gruttola V, Daar E, et al. A finite course of ART during early HIV-1 infection modestly delays need for subsequent ART initiation: ACTG A5217, the SETPOINT Study [abstract 134]. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections Program and Abstracts; February 16-19, 2010; San Francisco, CA.